BioSpace News Archive

Sosei Group Corporation (“Sosei Heptares"; TSE: 4565) and Verily, an Alphabet precision health technology company, today announced the successful validation and nomination of a first G-protein-coupled receptor (GPCR) target into early drug discovery for immune-mediated diseases with an initial indication focus of inflammatory bowel disease (IBD).

Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage precision oncology company developing therapies that target families of oncogenic mutations in patients with genetically defined cancers, today announced forthcoming presentations during the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, October 11-15, 2023.

Ryvu Therapeutics (WSE: RVU) today announced that preclinical data from its PRMT5 program and synthetic lethality platform as well as preclinical data on MEN1703 (SEL24) in B-cell lymphomas will be presented at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, October 11-15 in Boston, Massachusetts.

Prestige Medical Imaging is a leading provider of medical imaging technologies in the Eastern United States.

Genomma Lab Internacional, S.A.B. de C.V. (BMV: LABB) (“Genomma Lab” or “the Company”) today announced that it will report its Third Quarter 2023 results on Wednesday, October 25, 2023, after the Mexican Market (BMV) close.

Flare Therapeutics Inc. today announced a poster presentation highlighting an artificial intelligence-based model developed in partnership with PathAI that identifies the luminal subtype in Urothelial Carcinoma as a novel biomarker approach for its first-in-class clinical candidate FX-909 at the upcoming 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place October 11-15 in Boston, Massachusetts.

The U. S. Food and Drug Administration (FDA) has awarded Lipogems another Investigational Device Exemption (IDE) study for the use of MicroFat for the treatment of knee osteoarthritis (OA).

DELFI Diagnostics, Inc., a developer of accessible blood-based tests that deliver a new way to detect cancer, announced today that the company will participate in multiple sessions at the HLTH 2023 conference in Las Vegas, Nevada, and the CHEST 2023 Annual Meeting in Honolulu, Hawai’i, both taking place October 8-11, 2023.

Nautilus Life Science (USA) and HEMAP AG (Switzerland) today announced their partnership for the introduction of The Bridge©

Justera Health Ltd. (CSE: VTAL) (OTC Pink: SCRSF) (formerly ScreenPro Security Inc.) (“Justera” or the “Company”) is pleased to announce that its wholly-owned subsidiary, Naturevan Nutrition Ltd.